Fibroblast growth factor 21 was reported to have anti-hyperglycemic and anti-hyperlipidemic properties in diabetic rodent 13 and monkey 14 models, and hyperglycaemia and hyperlipidaemia were thought to be the major contributors to DCM 2. This evidence concerns the gene FGF21 and hyperlipidemia.